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280 Abstracts July 2013endovascular aneurysm repair (EVAR) for ruptured and non-ruptured
abdominal aortic aneurysm (AAA).
Design: This was a retrospective cohort study.
Methods: A total of 525 consecutive patients (73% elective) with
AAA underwent EVAR at two vascular centres from 2008 to 2011. From
registry data perioperative bleeding was analysed in relation to outcome
and preoperative data.
Results: A total of 453 (86%) patients presented with a perioperative
bleeding <1000 mL, 42 (8%) patients 1000-1999 mL, 19 (4%) patients
2000-5000 mL and 11 (2%) >5000 mL. Other than ruptured AAA
(n = 90), no preoperative risk factors for increased perioperative bleeding
were found. Open femoral artery access (n = 101), branched (n = 18)
and uni-iliacal endografts (n = 18) and introducer size were associated
with increased perioperative bleeding (P < .001). In multivariable logistic
regression only rupture and perioperative bleeding >2000 mL were signif-
icantly related to 30-day mortality (odds ratio 10.6 (range 3.8-29.6) and
13.4 (range 4.8-37.4), respectively). Postoperative renal failure, multi-organ
failure, >5 days at intensive care unit, bowel ischaemia and abdominal
compartments syndrome were signiﬁcantly related to perioperative bleeding
>2000 mL (P < .001).
Conclusion: Large perioperative bleeding during EVAR is a clinical
problem that affects outcome. About 10% of elective AAA patients and
34% of patients with ruptured AAA, undergoing EVAR, present a perioper-
ative blood loss exceeding 1 L. In our study, a perioperative blood loss
exceeding 2 L was independently associated with increased mortality and
morbidity in both acute and elective AAA patients. Open femoral access,
branched EVAR and larger diameter introducers were associated with
increased perioperative blood loss.
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Objective: To explore the associations between beta-blocker use and
clinical outcomes (death, hospitalisation with myocardial infarction (MI) or
stroke, major amputation and recurrent vascular surgery) after primary
vascular reconstruction.
Methods: Patients who had primary vascular surgical or endovascular
reconstruction due to symptomatic peripheral arterial disease, in Denmark
between 1996 and 2007 were included. We obtained data on ﬁlled prescrip-
tions, clinical outcomes and confounding factors from population-based
healthcare registries. Beta-blocker users were matched to non-users by
propensity score, and Cox-regression was performed. All medications
were included as time-dependent variables.
Results: We studied 16,945matched patients (7828 beta-blocker users
and 9117 non-users) with a median follow-up period of 582 days (range, 30-
4379 days). The cumulative risks were as follows: all-cause mortality, 17.9%;
MI, 5.3%; stroke, 5.6%; major amputation, 9.1%; and recurrent vascular
surgery, 23.1%.When comparing beta-blocker users with non-users: adjusted
hazard ratio: MI, 1.52 (95% CI, 1.31-1.78); stroke, 1.21 (95% CI,
1.03-1.43); and major amputation, 0.80 (95% CI, 0.70-0.93).
Conclusion: Beta-blocker use after primary vascular surgery was
associated with a lower risk of major amputation but an increased risk
of hospitalisation with MI and stroke. No associations were found
between beta-blocker use and all-cause mortality or the risk of recurrent
vascular surgery. However, our results are not sufﬁcient to alter the indi-
cation for beta-blocker use among symptomatic peripheral arterial disease
patients.
